Anthropic, the artificial intelligence startup behind the Claude AI assistant, is reportedly fielding investment offers that could value the company at up to $800 billion. According to Business Insider, multiple venture capitalists approached the company with proposals at that valuation within recent weeks, signaling a dramatic rise in investor enthusiasm for one of Silicon Valley's most closely watched AI firms.
This potential new valuation would represent a significant leap from the $380 billion figure attached to Anthropic's February funding round and would put it in close proximity to the $852 billion valuation that rival OpenAI secured during its March fundraise. The narrowing gap between the two companies reflects how competitive the generative AI landscape has become, with investors racing to back the most promising players.
Much of this renewed confidence stems from Anthropic's strong product momentum. The company has rolled out a series of sophisticated AI coding tools and agentic capabilities in recent months, drawing attention from enterprise customers and developers alike. Claude has also been steadily growing its user base, reinforcing its position as a serious contender in the consumer AI space.
Financially, Anthropic appears to be on a steep upward trajectory. The startup recently disclosed that its annualized revenue run rate now stands at $30 billion, a dramatic increase from the $9 billion reported at the end of 2025. That kind of growth rate is exactly what institutional investors look for when evaluating high-stakes technology bets.
Adding to the buzz, Anthropic announced last week that its newest model, Mythos, is too advanced for public release due to its power level. Access has been extended only to a select group of companies, a move that has only intensified curiosity and speculation around the model's capabilities.
The company continues to benefit from strategic backing by Amazon and Alphabet, two of the most influential technology giants in the world.


SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns
Unitree Shares Plunge 45% After Blockbuster IPO, Raising China Tech Bubble Fears
Countries Tighten Social Media Bans for Children
Nvidia Options Price in $280 Billion Earnings Swing
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
Jefferies Names AMEC Top China Semiconductor Equipment Pick
Alibaba Raises $10.2 Billion to Expand AI Infrastructure
Street Poller Media and The Boom of the Street Interview Ad Industry
PayPal Shares Sink as $50 Billion Takeover Bid Collapses
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing
Google Changes EU Spam Policy Amid Antitrust Scrutiny
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Mercer International Stock Surges 45% on C$20 Million Canada Funding 



